Calamos Advisors LLC Sells 44,567 Shares of Stryker Corporation $SYK

Posted by Geri Gentry on Nov 8th, 2026

Calamos Advisors LLC decreased its stake in Stryker Corporation (NYSE:SYK – Free Report) by 39.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 67,502 shares of the medical technology company’s stock after selling 44,567 shares during the period. Calamos Advisors LLC’s holdings in Stryker were worth $18,589,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the company. Gables Capital Management Inc. purchased a new stake in Stryker in the 2nd quarter worth about $25,000. Kilter Group LLC purchased a new stake in Stryker during the second quarter valued at about $25,000. Highland Investment Advisors LLC purchased a new stake in Stryker during the second quarter valued at about $25,000. Cornerstone Financial Management LLC boosted its position in Stryker by 66.0% during the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock worth $25,000 after purchasing an additional 31 shares during the period. Finally, Compass Financial Management LLC bought a new position in Stryker during the second quarter worth about $27,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 2.9%

Shares of SYK stock opened at $325.26 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 2.18. Stryker Corporation has a 52-week low of $267.00 and a 52-week high of $389.33. The company has a market capitalization of $123.83 billion, a PE ratio of 34.64, a price-to-earnings-growth ratio of 2.24 and a beta of 0.78. The business’s fifty day moving average is $292.37 and its 200 day moving average is $323.59.

Stryker (NYSE:SYK – Get Free Report) last posted its earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing the consensus estimate of $3.55 by ($0.03). The business had revenue of $6.52 billion for the quarter, compared to analysts’ expectations of $6.62 billion. Stryker had a return on equity of 23.74% and a net margin of 13.78%. Stryker’s quarterly revenue was up 7.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.19 earnings per share. On average, equities research analysts anticipate that Stryker Corporation will post 14.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Raymond James Financial reiterated an “outperform” rating and issued a $323.00 target price (down from $370.00) on shares of Stryker in a research note on Friday, October 30th. Leerink Partners dropped their price target on shares of Stryker from $403.00 to $353.00 and set an “outperform” rating on the stock in a research note on Friday, October 9th. TD Cowen cut their price objective on shares of Stryker from $298.00 to $290.00 and set a “hold” rating for the company in a report on Friday, October 30th. Rothschild & Co Redburn reduced their price objective on shares of Stryker from $360.00 to $336.00 in a research note on Monday, November 2nd. Finally, Wells Fargo & Company lowered their target price on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating on the stock in a report on Wednesday, September 9th. Twenty-one research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and a consensus target price of $343.73.

View Our Latest Report on SYK

Insider Activity

In related news, insider Debra King sold 826 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 50,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the sale, the director owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is currently owned by insiders.

About Stryker

(Free Report)

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings.

The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

Founded in 1941 by orthopedic surgeon Dr.